Ares Financial Consulting’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
Other funds holding CRL
Ares Financial Consulting's CRL Position: Q3 2026 in Review
Ares Financial Consulting held its Charles River Laboratories (CRL) position steady in Q3 2026 at 3 shares worth $885. The position accounts for ﹤0.01% of the portfolio, ranked #988.
Ares Financial Consulting first reported a position in CRL in Q4 2025 and has held it in 4 quarters since. 646 funds tracked by Wall St. Rank hold CRL as of Q3 2026.
- Ares Financial Consulting held 3 shares of Charles River Laboratories worth $885 as of Q3 2026.
- Ares Financial Consulting left its Charles River Laboratories share count unchanged in Q3 2026.
- Charles River Laboratories made up ﹤0.01% of Ares Financial Consulting's portfolio in Q3 2026, its #988 holding.
- Ares Financial Consulting first reported a position in Charles River Laboratories in Q4 2025 and has held it in 4 quarters since.
- 646 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2026.
Based on Ares Financial Consulting's 13F filing for Q3 2026, filed 19 Oct 2026.